Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposingLaura Riva, Sumit K. Chanda, Shuofeng Yuan et al.|Nature|2020Cited by 856
SARS-CoV-2 spike E484K mutation reduces antibody neutralisationSonia Jangra, Michael Schotsaert, Giulio Kleiner et al.|The Lancet Microbe|2021Cited by 435
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1AKris M. White, Adolfo García‐Sastre, Romel Rosales et al.|Science|2021Cited by 364
Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2Tia A. Tummino, Brian K. Shoichet, Veronica V. Rezelj et al.|Science|2021Cited by 223
Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune seraRaveen Rathnasinghe, Michael Schotsaert, Sonia Jangra et al.|Nature Communications|2022Cited by 41